L. Largeaud

发表

Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo

M. Record, C. Récher, M. Poirot, 2020, Cancers.

Clonal haematopoiesis is increased in early onset in systemic sclerosis.

C. Deswarte, M. Mohty, F. Delhommeau, 2020, Rheumatology.

GATA2 deficiency phenotype associated with tandem duplication of GATA2 and overexpression of GATA2-AS1

D. Rico, V. Bigley, B. Neven, 2021, Blood advances.

Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia

M. Carroll, J. Vial, C. Récher, 2022, Blood Cancer Journal.

Major rise of a chronic lymphoid leukemia clone during the course of COVID‐19

Y. Rolland, David Rousset, T. Geeraerts, 2020, International journal of laboratory hematology.

Outcome of relapsed/refractory AML patients with IDH1R132 mutations in real life before the era of IDH1 inhibitors

C. Récher, I. Luquet, V. Mas, 2020, Leukemia & lymphoma.

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine

L. Fornecker, C. Récher, I. Luquet, 2020, PloS one.

Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study

C. Récher, I. Luquet, S. Dimicoli-Salazar, 2022, Leukemia & lymphoma.

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

C. Récher, E. Delabesse, F. Vergez, 2019, Blood.

More than ten percent of relapses occur after five years in AML patients with NPM1 mutation

C. Récher, I. Luquet, E. Delabesse, 2020, Leukemia & lymphoma.

Dactinomycin in acute myeloid leukemia with NPM1 mutations.

C. Récher, I. Luquet, E. Delabesse, 2020, European journal of haematology.

Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia.

C. Preudhomme, Aurélie Caillault, C. Berthon, 2020, Blood.

The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11

O. Dovey, G. Vassiliou, L. Michaux, 2021, Blood advances.

CD34+CD38−CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents

C. Récher, I. Luquet, E. Delabesse, 2020, Cancers.

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.

J. Soulier, E. Clappier, H. Dombret, 2022, Blood.

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse

L. Ysebaert, M. Tosolini, J. Fournié, 2020, Biomarker Research.

Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study

J. Vial, C. Récher, I. Luquet, 2020, Cancers.

Genomic landscape of hyperleukocytic acute myeloid leukemia

C. Récher, I. Luquet, M. Picard, 2022, Blood cancer journal.

Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study

J. Vial, C. Récher, I. Luquet, 2020, Cancers.

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

M. Bernard, M. Béné, L. Fornecker, 2020, Leukemia.

VEXAS: is it time to reshape the nosology of clonal hematopoiesis?

O. Kosmider, P. Sujobert, M. Heiblig, 2023, Expert review of hematology.

UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

J. Soulier, E. Clappier, H. Dombret, 2023, Leukemia.

Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors.

C. Récher, I. Luquet, E. Delabesse, 2019, Leukemia research.

Somatic genetic alterations predict hematological progression in GATA2 deficiency

C. Bellanné-Chantelot, F. Delhommeau, I. Luquet, 2023, Haematologica.

Loss of HSC stemness identity is associated with exhaustion and hyporesponsiveness in GATA2 deficiency syndrome

E. Delabesse, C. Broccardo, N. Prade, 2023, bioRxiv.

Prognostic impact of unsupervised early assessment of bulk and leukemic stem cell measurable residual disease in acute myeloid leukemia.

J. Vial, M. Béné, C. Récher, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals.

C. Deswarte, M. Béné, F. Delhommeau, 2023, Clinical immunology.

Characteristic vacuolization of myeloid precursors and UBA1 mutation in a woman with monosomy X

I. Luquet, L. Sailler, L. Largeaud, 2021, International journal of laboratory hematology.

Stem cell–like reprogramming is required for leukemia-initiating activity in B-ALL

A. Khamlichi, I. Luquet, C. Broccardo, 2023, The Journal of experimental medicine.

Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy

C. Récher, I. Luquet, A. Bidet, 2024, Cancer medicine.

Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms

M. Fontenay, D. Bouscary, O. Kosmider, 2024, Leukemia.

Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.

I. Luquet, A. Bidet, J. Alliot, 2024, Leukemia research.

Occurrence of a paroxysmal nocturnal hemoglobinuria clone in an essential thrombocythemia: a link between PIGV and MPL

Alexej Knaus, B. Payrastre, H. Engels, 2022, Haematologica.

Vitamin C and D supplementation in acute myeloid leukemia

C. Récher, I. Luquet, Noémie Gadaud, 2023, Blood advances.

S162: SOMATIC GENETIC LANDSCAPE IN GATA2 DEFICIENCY PATIENTS

C. Bellanné-Chantelot, F. Delhommeau, C. Fieschi, 2022, HemaSphere.

New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling

L. Ysebaert, A. Quillet-Mary, L. Largeaud, 2024, PLoS medicine.